Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
ASX Announcements
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Investor Newsletters
Corporate Governance
Shareholder Services
Media Centre
Overview
Latest News
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
Media Centre
>
Latest News
Overview
Latest News
Video
Coverage
Latest News
Filter by Year:
2023
2022
2021
2020
15-Jun-2021
Kazia Enters Clinical Collaboration With Cornell University For Phase Ii Clinical Study Using Paxalisib In Combination With Ketogenic Diet For Glioblastoma
7-Jun-2021
Study Of Paxalisib In Primary Cns Lymphoma At Dana-Farber Cancer Institute Enrols First Patient
19-Apr-2021
Kazia Licenses Global Rights To Evt801, A Novel, First-In-Class, Clinic-Ready, Vegfr3 Inhibitor, From Evotec Se
29-Mar-2021
Kazia Licenses Rights To Paxalisib In Greater China To Simcere, A Leading Chinese Pharmaceutical Company
1-Mar-2021
Kazia Licenses Cantrixil, A Clinical-Stage, First-In-Class Ovarian Cancer Drug Candidate, To Oasmia Pharmacetical Ab
7-Jan-2021
Gbm Agile Pivotal Study Commences Recruitment To Paxalisib Arm
20-Dec-2020
Kazia Therapeutics Limited Appendix 4D Half-year report
Previous
1
2
3
4
5
